Hemab Therapeutics Holdings, Inc. Common Stock (COAG) vs Cronos Group Inc. (CRON)

A side-by-side comparison of Hemab Therapeutics Holdings, Inc. Common Stock and Cronos Group Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Hemab Therapeutics Holdings, Inc. Common Stock logo
COAG
Hemab Therapeutics Holdings, Inc. Common Stock
$1.33B
$28.55HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
Cronos Group Inc. logo
CRON
Cronos Group Inc.
$1.22B
$3.28HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT

Total return — COAG vs CRON

growth of $100 · dividends reinvested · last 1y
COAG -10.0% (-10.0%/yr)CRON +26.0% (+26.0%/yr)CRON compounded faster over this window
80100120140160Start $100$90$126
COAG CRON

COAG vs CRON: by the numbers

  • •COAG is the larger company ($1.33B vs $1.22B market cap).
  • •CRON is profitable (30.98% net margin) while COAG runs a net loss (0.00%).

Metrics side by side

Valuation

MetricCOAGCRON
P/E ratioN/A18.08
P/S ratioN/A5.43
P/B ratio2.941.15
EV / EBITDAN/A27.95
FCF yieldN/A4.06%

Profitability

MetricCOAGCRON
Gross margin0.00%36.16%
Operating margin0.00%-11.96%
Net margin0.00%30.98%
ROEN/A6.53%
ROIC-38.09%1.12%

Growth (annualized)

MetricCOAGCRON
Revenue CAGR (5Y)N/A31.80%
Total return CAGR (5Y)N/A-9.92%

Frequently asked

Is COAG or CRON more profitable?
CRON runs the higher net margin — COAG at 0.00% versus CRON at 30.98%.

Go deeper

Full COAG analysisFull CRON analysisInteractive comparison tool

Dig into the metrics

Cronos P/E ratioHemab Therapeutics Holdings, Inc. Common Stock ROECronos ROEHemab Therapeutics Holdings, Inc. Common Stock operating marginCronos operating marginHemab Therapeutics Holdings, Inc. Common Stock revenue growthCronos revenue growthHemab Therapeutics Holdings, Inc. Common Stock free cash flowCronos free cash flow

Hemab Therapeutics Holdings, Inc. Common Stock & Cronos appear in these rankings

Fastest Revenue Growth StocksHighest FCF Yield StocksHighest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.